{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-016652","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.020969+00:00","generated_at":"2026-05-15T14:44:44.586224+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vistagen cuts workforce 20%, cites cash management; PALISADE-4 results expected H1 2026","bullets":["Reduced workforce by approximately 20% to prioritize fasedienol PALISADE-4 Phase 3 trial.","Topline results from PALISADE-4 for social anxiety disorder expected first half of 2026.","Company expects cash runway to extend into 2027 after the workforce reduction.","Affected employees may receive cash severance and healthcare coverage; costs expected immaterial."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-016652","json":"https://secwatch.observer/filing/0001628280-26-016652.json","markdown":"https://secwatch.observer/filing/0001628280-26-016652.md","text":"https://secwatch.observer/filing/0001628280-26-016652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026016652/0001628280-26-016652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026016652/vtgn-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:44:44.586224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}